Pegvaliase


Pegvaliase is a medication for the treatment of the genetic disease phenylketonuria. Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.
It was approved by the Food and Drug Administration for use in the United States in 2018.